{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:18:15Z","timestamp":1788049095963,"version":"build-2784847793"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002865","name":"Chongqing Municipal Science and Technology Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejmech.2026.119161","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:16:13Z","timestamp":1784906173000},"page":"119161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design, synthesis, and biological evaluation of pyrrolo[2,3-c]pyridin-7-one derivatives as PKMYT1 inhibitors targeting CCNE1-amplified cancers"],"prefix":"10.1016","volume":"318","author":[{"given":"Jiayi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfeng","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangrui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changde","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shizhu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9081-3683","authenticated-orcid":false,"given":"Pengfei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119161_bib1","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1002\/cncr.33587","article-title":"The ever-increasing importance of cancer as a leading cause of premature death worldwide","volume":"127","author":"Bray","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2026.119161_bib2","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1080\/10717544.2022.2094498","article-title":"Nano-drug co-delivery system of natural active ingredients and chemotherapy drugs for cancer treatment: a review","volume":"29","author":"Li","year":"2022","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejmech.2026.119161_bib3","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41392-021-00648-7","article-title":"DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.119161_bib4a","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nrg.2017.47","article-title":"Synthetic lethality and cancer","volume":"18","author":"O'Neil","year":"2017","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ejmech.2026.119161_bib4b","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1086\/279847","article-title":"The origin of variations in sexual and sex-limited characters","volume":"56","author":"Bridges","year":"1922","journal-title":"Am. Nat."},{"key":"10.1016\/j.ejmech.2026.119161_bib4c","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/genetics\/31.3.269","article-title":"Genetics of natural populations; recombination and variability in populations of Drosophila pseudoobscura","volume":"31","author":"Dobzhansky","year":"1946","journal-title":"Genetics"},{"key":"10.1016\/j.ejmech.2026.119161_bib5","first-page":"1","article-title":"PARP inhibitors for ovarian cancer: current indications, future combinations, and novel assets in development to target DNA damage repair","volume":"40","author":"Konstantinopoulos","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.ejmech.2026.119161_bib6","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119161_bib7","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41586-024-07217-2","article-title":"Transcription\u2013replication conflicts underlie sensitivity to PARP inhibitors","volume":"628","author":"Petropoulos","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119161_bib8","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1200\/JCO.22.01003","article-title":"A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer","volume":"40","author":"Monk","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119161_bib9","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","article-title":"Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial","volume":"35","author":"Monk","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2026.119161_bib10","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/s43018-022-00439-1","article-title":"A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes","volume":"3","author":"Gruber","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ejmech.2026.119161_bib11","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-021-01541-x","article-title":"Fuzuloparib: first approval","volume":"81","author":"Lee","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.119161_bib12","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s40265-021-01552-8","article-title":"Pamiparib: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.119161_bib13","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41392-020-00358-6","article-title":"Development of synthetic lethality in cancer: molecular and cellular classification","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.119161_bib14","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1056\/NEJMra1407390","article-title":"Applying synthetic lethality for the selective targeting of cancer","volume":"371","author":"McLornan","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119161_bib22","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41586-022-04638-9","article-title":"CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition","volume":"604","author":"Gallo","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119161_bib15a","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.3390\/molecules22122045","article-title":"Regulation of G2\/M Transition by Inhibition of WEE1 and PKMYT1 Kinases","volume":"22","author":"Schmidt","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119161_bib15b","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1126\/science.270.5233.86","article-title":"Myt1: a membrane-associated inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15","volume":"270","author":"Mueller","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119161_bib16","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13045-020-00959-2","article-title":"A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target","volume":"13","author":"Ror\u00e0","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2026.119161_bib17","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/d41573-019-00202-9","article-title":"PKMYT1: a forgotten member of the WEE1 family","volume":"19","author":"Asquith","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119161_bib18","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/0092-8674(93)80048-J","article-title":"Human wee1 maintains mitotic timing by protecting the nucleus from cytoplasmically activated Cdc2 kinase","volume":"74","author":"Heald","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119161_bib19","article-title":"Myt1 kinase inhibitors - insight into structural features, offering potential frameworks","volume":"391","author":"Pavlovi","year":"2024","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2026.119161_bib20a","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cancergen.2017.06.002","article-title":"Gene expression profiling, pathway analysis and subtype classification reveal molecular heterogeneity in hepatocellular carcinoma and suggest subtype specific therapeutic targets","volume":"216\u2013217","author":"Agarwal","year":"2017","journal-title":"Cancer Genet."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119161_bib20b","first-page":"4210","article-title":"Overexpression of PKMYT1 indicates the poor prognosis and enhances proliferation and tumorigenesis in non-small cell lung cancer via activation of Notch signal pathway","volume":"23","author":"Sun","year":"2019","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2026.119161_bib20c","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1002186","article-title":"Overexpression of PKMYT1 associated with poor prognosis and immune infiltration may serve as a target in triple-negative breast cancer","volume":"12","author":"Li","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2026.119161_bib21","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1038\/onc.2012.504","article-title":"The CDK1 inhibitory kinase MYT1 in DNA damage checkpoint recovery","volume":"32","author":"Chow","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2026.119161_bib23","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1016\/j.bmc.2018.06.027","article-title":"Identification of PKMYT1 inhibitors by screening the GSK published protein kinase inhibitor set I and II","volume":"26","author":"Platzer","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119161_bib24","first-page":"8211","article-title":"Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator","volume":"61","author":"Wang","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119161_bib25a","doi-asserted-by":"crossref","first-page":"10251","DOI":"10.1021\/acs.jmedchem.2c00552","article-title":"Discovery of an orally bioavailable and selective PKMYT1 inhibitor, RP-6306","volume":"65","author":"Szychowski","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119161_bib26","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1021\/acs.jmedchem.3c01476","article-title":"Discovery of tetrahydropyrazolopyrazine derivatives as potent and selective myt1 inhibitors for the treatment of cancer","volume":"67","author":"Wang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119161_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117025","article-title":"Discovery of pyrrolopyrimidinone derivatives as potent PKMYT1 inhibitors for the treatment of cancer","volume":"281","author":"Wang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119161_bib28a","article-title":"Discovery of a bifunctional PKMYT1-targeting PROTAC empowered by AI-generation","volume":"16","author":"Wang","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119161_bib28b","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2026.118582","article-title":"Conformational restriction of hinge carboxamide leading to potent lactam-based PKMYT1 inhibitors","volume":"135","author":"Wang","year":"2026","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119161_bib28c","article-title":"An internal sulfur\u2013lone pair interaction enabled the discovery of potent and sub-family selective PKMYT1 inhibitors","volume":"21","author":"Wang","year":"2026","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2026.119161_bib29","doi-asserted-by":"crossref","first-page":"15816","DOI":"10.1021\/acs.jmedchem.4c01458","article-title":"Structure-based drug design of 2-amino-[1,1\u2032-biphenyl]-3-carboxamide derivatives as selective PKMYT1 inhibitors for the treatment of CCNE1-amplified breast cancer","volume":"67","author":"Zhang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119161_bib30","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1039\/D4MD00389F","article-title":"Structure-based virtual screening discovers novel PKMYT1 inhibitors","volume":"15","author":"Zhang","year":"2024","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119161_bib31a","article-title":"Discovery of potent and selective PKMYT1 inhibitors for the treatment of CCNE1-amplified cancer","volume":"290","author":"Zhang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119161_bib31b","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.3390\/biomedicines13092116","article-title":"Design, Synthesis, and Computational Insights into PKMYT1 Inhibitors for the Treatment of Breast Cancer","volume":"13","author":"Yu","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejmech.2026.119161_bib32","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1021\/acs.jmedchem.5c01298","article-title":"Discovery of tetracyclic derivatives as highly potent, selective, and bioavailable PKMYT1 inhibitors for cancer therapy","volume":"69","author":"Zhu","year":"2026","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119161_bib33","first-page":"228","article-title":"Discovery of PKMYT1 inhibitors with a novel scaffold for the treatment of triple-negative breast cancer","volume":"69","author":"Huang","year":"2026","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119161_bib34","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1021\/acs.joc.6c00304","article-title":"Enantioselective Suzuki\u2013Miyaura chemistry: route evolution for the synthesis of PKMYT1 inhibitor XL495","volume":"91","author":"Jiang","year":"2026","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2026.119161_bib35a","series-title":"Compounds that inhibit PKMYT1","author":"Xu","year":"2024"},{"key":"10.1016\/j.ejmech.2026.119161_bib35b","series-title":"Indazole compounds as PKMYT1 kinase inhibitors","author":"Chen","year":"2024"},{"key":"10.1016\/j.ejmech.2026.119161_bib35c","series-title":"Pyrrolopyrimidine carboxamides","author":"Ghosh","year":"2024"},{"key":"10.1016\/j.ejmech.2026.119161_bib35d","series-title":"Nitrogen-containing heterocyclic compound having MYT1 inhibitory activity","author":"Aoki","year":"2024"},{"key":"10.1016\/j.ejmech.2026.119161_bib35e","series-title":"Phenyl-pyrazole carboxamide compounds","author":"Rosensch\u00f6ld","year":"2024"},{"key":"10.1016\/j.ejmech.2026.119161_bib36","doi-asserted-by":"crossref","first-page":"6679","DOI":"10.1021\/acs.jmedchem.9b02052","article-title":"Identification of the clinical development candidate mrtx849, a covalent KRAS G12C inhibitor for the treatment of cancer","volume":"63","author":"Fell","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119161_bib37","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1021\/acs.jmedchem.5b00734","article-title":"Fragment-based discovery of a small molecule inhibitor of Bruton's tyrosine kinase","volume":"58","author":"Smith","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119161_bib38","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1021\/acs.jmedchem.0c01858","article-title":"Structure-based approaches to improving selectivity through utilizing explicit water molecules: discovery of selective \u03b2-secretase (BACE1) inhibitors over BACE2","volume":"64","author":"Fujimoto","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119161_bib39","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","article-title":"Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165","volume":"62","author":"Wrobleski","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119161_bib40","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","article-title":"AutoDock Vina 1.2.0: new docking methods, expanded force field, and python bindings","volume":"61","author":"Eberhardt","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.119161_bib41","article-title":"Crystal structure reveals the hydrophilic R1 group impairs NDM-1\u2013ligand binding via water penetration at L3","volume":"12","author":"Shi","year":"2025","journal-title":"J. Struct. Biol. X."},{"key":"10.1016\/j.ejmech.2026.119161_bib42","article-title":"COMP 114-Novel algorithms enabling practical microsecond-scale molecular dynamics simulations","volume":"vol. 235","author":"Bowers","year":"2008"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:13:30Z","timestamp":1788048810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426006069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":54,"alternative-id":["S0223523426006069"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119161","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and biological evaluation of pyrrolo[2,3-c]pyridin-7-one derivatives as PKMYT1 inhibitors targeting CCNE1-amplified cancers","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119161","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119161"}}